Latest Ratios: P/E Ratio -0.0x · EV/EBITDA N/A · ROE N/A. (2020–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $1.3B | $799M | $1M | $877527 | $14M | — | — |
| Enterprise Value | $1.2B | $697M | $-354289 | $-2251491 | $8M | — | — |
| P/E Ratio → | -0.04 | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — |
| P/B Ratio | — | — | 0.14 | 0.08 | 0.14 | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | — | — | -96099.4% | -177.0% | -32.1% | — | — |
| ROA | -13542.7% | -13542.7% | -44076.9% | -139.8% | -23.5% | -892.4% | -1850.0% |
| ROIC | — | — | -91789.9% | -21.2% | -22.9% | — | — |
| ROCE | — | — | -85841.8% | -23.6% | -28.3% | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | 0.00 | 0.00 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | -0.18 | -0.28 | -0.06 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | -49.28 | -49.28 | -33908.17 | — | -33.77 | -8.84 | -23.56 |
Net cash position: cash ($102M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 0.03 | 0.03 | 0.15 | 0.33 | 0.78 | 0.06 | 0.04 |
| Quick Ratio | 0.03 | 0.03 | 0.15 | 0.33 | 0.78 | 0.06 | 0.04 |
| Cash Ratio | 0.01 | 0.01 | 0.14 | 0.31 | 0.72 | 0.02 | 0.02 |
| Asset Turnover | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 100.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 100.0% | 0.0% | — | — |
| Shares Outstanding | — | $6.0B | $1M | $97503 | $25948 | $46552 | $46552 |
Binary clinical trial failure
As reported in financial statements, ZVSA's ROIC has consistently remained in deep negative territory, reaching -244.4% in 2025Q2, which underscores the firm's inability to generate returns on invested capital while it remains in the high-cost, pre-revenue phase of its clinical development lifecycle.
The persistent negative ROIC reflects the massive R&D expenditures required to advance the VAR 200 and IC 100 programs without any offsetting commercial revenue. Investors should interpret these figures as a clear indicator that the company is currently a capital-consuming entity rather than a value-compounding one, with no immediate path to positive returns until clinical milestones are achieved.
Based on recent SEC filings, the company's current ratio has deteriorated to a precarious 0.05 as of 2026Q1, indicating that current assets are insufficient to cover short-term obligations and highlighting the extreme sensitivity of the firm's operations to the timing of future capital raises.
The rapid decline in liquidity ratios suggests that the company is operating with a very thin margin for error regarding its cash management. This liquidity profile warrants close monitoring, as any unexpected increase in clinical trial costs or delays in regulatory progress could force the company to seek dilutive financing under unfavorable market conditions.
According to historical data, the company's DPO has fluctuated significantly, reaching 65,696 days in 2024Q4, which, as noted in financial disclosures, is a byproduct of the firm's pre-revenue status rather than an indication of actual supplier leverage or efficient working capital management.
The extreme volatility in payables metrics is typical for a clinical-stage biotech where operational activity is driven by lumpy milestone payments to CROs rather than recurring trade cycles. Analysts should avoid interpreting these efficiency ratios as indicators of operational maturity, as they are currently distorted by the lack of a standard commercial business cycle.
As indicated by the company's financial profile, the use of P/E or EV/EBITDA ratios is fundamentally inappropriate for ZVSA, as these metrics obscure the binary nature of the firm's clinical-stage assets and the lack of current earnings or operational cash flow.
Investors frequently misapply earnings-based multiples to ZVSA, which fails to account for the probability-adjusted net present value of the pipeline. A more appropriate analytical framework would involve assessing the cash-to-market-cap ratio and the clinical runway, rather than attempting to derive value from non-existent profitability metrics that do not reflect the company's true economic potential.
Includes 30+ ratios · 6 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ZVSA stock.
ZyVersa Therapeutics, Inc.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
Based on historical data, ZyVersa Therapeutics, Inc. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.